Navigation Links
Dendreon Announces Webcast Presentation at Newsmakers in the Biotech Industry Conference
Date:8/29/2008

SEATTLE, Aug. 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that Greg Schiffman, chief financial officer of Dendreon, will present a company update at the Newsmakers in the Biotech Industry Conference in New York City, on Thursday, September 4, 2008 at 3:55 p.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Dendreon website, http://www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
2. Dendreon Reports First Quarter 2008 Financial Results
3. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
4. Dendreon Announces Closing of Registered Direct Offering
5. Dendreon Announces $47 Million Registered Direct Offering
6. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
7. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
8. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
9. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
10. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
11. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... BARBARA, CALIFORNIA (PRWEB) , ... April 20, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is pleased to announce ... the new established USDM subsidiary “USDM Europe GmbH” based in Germany. , Braemer ...
(Date:4/20/2017)... - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or ... Congress ("ILC") 2017 of the European Association for the Study ... on the positive effects of PBI-4050 on reduction of non-alcoholic ... syndrome. ... Lyne Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive ...
(Date:4/20/2017)... MD (PRWEB) , ... April 20, 2017 , ... ... the formation of a unique intellectual property (IP) sharing and commercialization model. , ... most promising inventions. A main component of this effort is bringing the IP ...
(Date:4/20/2017)... 2017 For today, Stock-Callers.com redirects investors, ... development and clinical research aimed at treating diseases and medical ... Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite Pharma Inc. (NASDAQ: KITE), ... can access our complimentary research reports on these stocks now ... http://stock-callers.com/registration ...
Breaking Biology Technology:
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):